Becker's Healthcare December 7, 2023
Paige Twenter

Out of the hundreds of new drugs entering the U.S. market, eight made tailwinds in the healthcare industry, according to GoodRx.

Note: This list does not include notable FDA approvals in December.

1. Paxlovid (nirmatrelvir/ritonavir) for COVID-19: In late May, the COVID-19 antiviral treatment gained FDA approval after being on the market since December 2021 with an emergency use authorization. It’s the first-choice treatment option for nonhospitalized patients 12 and older, according to the National Institutes of Health.

2. Arexvy, Abrysvo and Beyfortus for respiratory syncytial virus: Before 2023, the only drug approved for RSV was Synagis (palivizumab), which is only indicated for high-risk patients. Arexvy (RSVPreF3) is the first FDA-approved RSV vaccine, and RSV vaccine Abrysvo (RSVpreF)...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article